Table 1 Demographics, clinical characteristics, and drug use for study patientsa
Characteristic | Number of patients (%), unless otherwise stated | |||||
|---|---|---|---|---|---|---|
Study 1 | Study 2 | Pooledb | ||||
Doripenem (n = 63) | Pip/Tazo (n = 61) | Doripenem (n = 249) | Imipenem (n = 252) | Doripenem (n = 312) | Comparator (n = 313) | |
Mean age, years (SD) | 50.8 (20.1) | 54.0 (20.4) | 51.4 (19.8) | 51.7 (18.7) | 51.3 (19.8) | 52.2 (19.0) |
Men | 42 (66.7) | 46 (75.4) | 195 (78.3) | 192 (76.2) | 237 (76.0) | 238 (76.0) |
APACHE II ≤15 | 35 (55.6) | 32 (52.5) | 117 (47.0) | 120 (47.6) | 152 (48.7) | 152 (48.6) |
Race | ||||||
White | 39 (61.9) | 40 (65.6) | 217 (87.1) | 209 (82.9) | 256 (82.1) | 249 (79.6) |
Black | 7 (11.1) | 3 (4.9) | 22 (8.8) | 28 (11.1) | 29 (9.3) | 31 (9.9) |
Hispanic | 16 (25.4) | 17 (27.9) | 9 (3.6) | 10 (4.0) | 25 (8.0) | 27 (8.6) |
Other | 1 (1.6) | 1 (1.6) | 1 (0.4) | 5 (2.0) | 2 (0.6) | 6 (1.9) |
VAP onset | ||||||
Early (<5 days) | 63 (100.0) | 61 (100.0) | 98 (39.4) | 97 (38.5) | 161 (51.6) | 158 (50.5) |
Late (≥5 days) | 0 (0.0) | 0 (0.0) | 151 (60.6) | 155 (61.5) | 151 (48.4) | 155 (49.5) |
Adjunctive drug usage | ||||||
Amikacin | 52 (82.5) | 51 (83.6) | 28 (11.2) | 40 (15.9) | 80 (25.6) | 91 (29.1) |
Vancomycin | 18 (28.6) | 13 (21.3) | 70 (28.1) | 74 (29.4) | 88 (28.2) | 87 (27.8) |
Oral levofloxacin | 9 (14.3) | 7 (11.5) | Not applicable | 9 (2.9) | 7 (2.2) | |
Baseline microbiologyc | ||||||
Pseudomonas aeruginosa | 6 (9.5) | 11 (18.0) | 30 (12.0) | 26 (10.3) | 36 (11.5) | 37 (11.8) |
MRSA | 6 (9.5) | 3 (4.9) | 14 (5.6) | 16 (6.3) | 20 (6.4) | 19 (6.1) |
Surgery | 45 (71.4) | 41 (67.2) | 193 (77.5) | 194 (77.0) | 238 (76.3) | 235 (75.1) |